NHS England now offers the "Trojan horse" therapy, belantamab mafodotin (Blenrep) for patients with multiple myeloma.

This FTSE 100 pharmaceutical giant has been hit by fears of US tariffs and litigation over a key product, but this could mean ...

GSK (LSE:GSK) announced that the European Medicines Agency accepted its regulatory application to expand the use of its RSV ...

GSK's regulatory filing for expanded use of RSV vaccine, Arexvy, in adults aged 18 years and older has been accepted for ...

GSK PLC closed 11.51% short of its 52-week high of £16.79, which the company achieved on September 9th.

GSK’s Blenrep (belantamab mafodotin) has been recommended by the National Institute for Health and Care Excellence (NICE) as ...

GSK has applied to the European Medicines Agency to expand use of its respiratory syncytial virus (RSV) vaccine to adults ...

GSK has licensed altSonflex1-2-3, its Shigella vaccine candidate, to Bharat Biotech for the continued development and ...

Arexvy is already approved in the European Economic Area for the prevention of lower respiratory tract disease (LRTD) caused ...

The US Food and Drug Administration (FDA) announced a forthcoming public advisory committee meeting (AdCom) of the Oncologic Drugs Advisory Committee to review GSK’s marketing application for Blenrep ...

England is the first country in the world to make GSK's anti-BCMA drug Blenrep available to patients with the haematological ...

In a world grappling with urgent health threats, these youth advocates are offering bold solutions and renewed hope for the future.